Health News

Seattle Genetics, Inc. and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today reported preclinical data with ASG-5ME, an antibody-drug conjugate (ADC) that is being co-developed by both companies for the treatment of solid tumors. In models of human prostate and pancreatic cancer, ASG-5ME was found to have potent and long lasting antitumor activity. The findings were presented at the 101st Annual Meeting of the American Association for Cancer Research (AACR) being held in Washington, D.C.

Read more

Filed under: Pharmacy News
Tags: cancer, Drug, Genetic, Pharmacy, Tumor

Related posts

• Study finds Olaparib can reduce tumor size in ovarian cancer women (0)
  Understanding the underlying genetic weakness of certain types of cancer may lead to targeted therapy and provide the key to effective treatment, a new study suggests. An international consortium of researchers has shown that an investigational drug, Olaparib, can reduce the size of tumors in women with advanced hereditary ovarian cancer with BRCA gene mutations. Read [...]
  
  
• Seattle Genetics, Agensys commence ASG-5ME ADC phase I clinical trial for metastatic pancreatic cancer (0)
  Seattle Genetics, Inc. and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today announced that they have initiated a phase I clinical trial of ASG-5ME for the treatment of metastatic pancreatic cancer. ASG-5ME is an antibody-drug conjugate (ADC) that is being co-developed by both companies for the treatment of solid tumors. Read more [tags] Pharmacy News [...]
  
  
• Seattle Genetics Presents Preclinical Data on Antibody-Drug Conjugate Programs at AACR (0)
  Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that data from its antibody-drug conjugate (ADC) programs, SGN-35 and SGN-75, were presented at the 2009 Annual Meeting of the American Association for Cancer Research (AACR) being held in Denver, CO. Preclinical data with SGN-35 further elucidate its mechanism of action and demonstrate its superior antitumor activity in [...]
  
  
• Seattle Genetics Presents Preclinical Data on Antibody-Drug Conjugate Programs at AACR (0)
  Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that data from its antibody-drug conjugate (ADC) programs, SGN-35 and SGN-75, were presented at the 2009 Annual Meeting of the American Association for Cancer Research (AACR) being held in Denver, CO. Preclinical data with SGN-35 further elucidate its mechanism of action and demonstrate its superior antitumor activity in [...]
  
  
• Genes Identified That Enhance Tumor Cell Sensitivity To CTI’s Cancer Drug Brostallicin (0)
  Systems Medicine, LLC (SM), a wholly-owned subsidiary of Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC), presented data from a preclinical study, which utilized RNA interference (RNAi) and bioinformatics to identify genetic markers - "contexts of vulnerability" - that enhance the anti-tumor response to the experimental drug candidate brostallicin, at the 2009 American Association for [...]